-
01:54:07 PM

PULM Stock News

07/11/23 9:05 AM
Nasdaq : PULM
clinical triallow float
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Pulmatrix, Inc., a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease, today announced the submission of an investigational new drug application to the United States Food and Drug Administration for PUR3100, an...
RHEA-AI
neutral
02/06/23 9:10 AM
Nasdaq : PULM
clinical triallow float
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
Pulmatrix, Inc., a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the first patient dosed in a Phase 2 b trial evaluating safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis and asthma.
RHEA-AI
neutral